31,116 resources
By Version
By Authority
By Realm
Start Prev Rows 6600 - 6800 Next
Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Auth | Source(s) |
---|---|---|---|---|---|---|---|---|---|---|
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.183 | Cardiac Pacer in Situ | active | 2021-02 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.185 | Hypotension | active | 2025-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.186 | Arrhythmia | active | 2025-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.187 | Atrioventricular Block | active | 2025-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.1912 | Major Depressive Disorder Active | active | 2023-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.1918 | Major Depressive Disorder Active | active | 2023-02 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.1923 | Psych Visit Diagnostic Evaluation | active | 2017-05 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.1924 | Cardiac Pacer in Situ | active | 2023-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.408 | Bradycardia | active | 2024-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.410 | Bradycardia | active | 2017-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.411 | Bradycardia | active | 2017-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.422 | Tobacco User | active | 2024-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.423 | Tobacco Use Cessation Pharmacotherapy | active | 2025-01 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.424 | Tobacco Use Cessation Counseling | active | 2017-05 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.425 | Tobacco Use Cessation Counseling | active | 2023-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.450 | Pain Warranting Further Investigation for Prostate Cancer | active | 2023-02 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.469 | Bilateral Oophorectomy | active | 2017-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.470 | Bilateral Oophorectomy | active | 2024-01 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.483 | Chemotherapy | active | 2024-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.484 | Chemotherapy | active | 2021-08 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.511 | Tobacco Non User | active | 2024-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.532 | Pregnancy | active | 2025-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.56 | Coronary Artery Disease No MI | active | 2017-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.57 | Coronary Artery Disease No MI | active | 2024-02 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.58 | Initial Myocardial Infarction | active | 2024-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.589 | End Stage Renal Disease | active | 2017-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.59 | Asthma | active | 2017-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.590 | End Stage Renal Disease | active | 2017-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.60 | Asthma | active | 2017-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.61 | Asthma | active | 2025-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.73 | Primary Open Angle Glaucoma | active | 2021-02 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.74 | Primary Open Angle Glaucoma | active | 2025-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.76 | Diabetic Retinopathy | active | 2021-02 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.80 | Diabetic Retinopathy | active | 2025-01 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.859 | Left Ventricular Systolic Dysfunction | active | 2017-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.860 | Moderate or Severe | active | 2017-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.861 | Moderate or Severe LVSD | active | 2017-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.91 | Prostate Cancer | active | 2017-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.92 | Prostate Cancer | active | 2025-03 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1002 | Chronic Kidney Disease, Stage 5 | active | 2020-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1005 | Dementia and Mental Degenerations | active | 2020-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1006 | Standardized Tools Score for Assessment of Cognition | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1007 | Medical Reason | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1008 | Patient Reason | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1010 | Cancer | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1011 | Occupational Therapy Evaluation | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1012 | Patient Provider Interaction | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1018 | Psych Visit for Family Psychotherapy | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1023 | Behavioral or Neuropsych Assessment | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1026 | Radiation Treatment Management | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1027 | Chemotherapy Administration | active | 2024-01 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1028 | Standardized Pain Assessment Tool | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1090 | Moderate or Severe LVSD | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1091 | Left Ventricular Systolic Dysfunction | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1092 | Moderate or Severe | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1134 | Ejection Fraction | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1139 | ACE Inhibitor or ARB or ARNI | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1140 | Patient Reason for ACE Inhibitor or ARB Decline | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1141 | Psychoanalysis | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1151 | Renal Failure Due to ACE Inhibitor | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1170 | Tobacco User | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1174 | Beta Blocker Therapy | active | 2021-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1176 | Heart Rate | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1177 | Allergy to Beta Blocker Therapy | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1178 | Intolerance to Beta Blocker Therapy | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1184 | Beta Blocker Therapy for LVSD | active | 2017-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1187 | Group Psychotherapy | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1189 | Tobacco Non User | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1190 | Tobacco Use Cessation Pharmacotherapy | active | 2017-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1193 | Cardiac Pacer | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1211 | Allergy to ACE Inhibitor or ARB | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1212 | Intolerance to ACE Inhibitor or ARB | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1240 | Annual Wellness Visit | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1241 | Acute and Subacute Iridocyclitis | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1251 | Macular Exam | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1259 | Limited Life Expectancy | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1278 | Tobacco Use Screening | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1283 | Level of Severity of Retinopathy Findings | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1285 | Ophthalmological Services | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1320 | Macular Edema Findings Present | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1332 | Cognitive Assessment | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1333 | Cup to Disc Ratio | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1334 | Optic Disc Exam for Structural Abnormalities | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1409 | Burn Confined to Eye and Adnexa | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1410 | Cataract Secondary to Ocular Disorders | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1411 | Cataract Surgery | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1412 | Cataract Congenital | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1413 | Cataract Mature or Hypermature | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1414 | Cataract Posterior Polar | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1415 | Certain Types of Iridocyclitis | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1416 | Chronic Iridocyclitis | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1417 | Cloudy Cornea | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1418 | Corneal Edema | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1419 | Disorders of Cornea Including Corneal Opacity | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1423 | Glaucoma | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1424 | Hereditary Corneal Dystrophies | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1426 | Hypotony of Eye | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1427 | Injury to Optic Nerve and Pathways | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1428 | Central Corneal Ulcer | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1430 | Open Wound of Eyeball | active | 2021-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1432 | Pathologic Myopia | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1433 | Posterior Lenticonus | active | 2021-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1438 | Retrolental Fibroplasias | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1443 | Traumatic Cataract | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1444 | Uveitis | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1445 | Vascular Disorders of Iris and Ciliary Body | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1446 | Visual Field Defects | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1448 | Amblyopia | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1450 | Choroidal Degenerations | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1451 | Choroidal Detachment | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1452 | Choroidal Hemorrhage and Rupture | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1453 | Degeneration of Macula and Posterior Pole | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1454 | Degenerative Disorders of Globe | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1455 | Diabetic Macular Edema | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1457 | Disorders of Optic Chiasm | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1458 | Disorders of Visual Cortex | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1459 | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1460 | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1461 | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1462 | Hereditary Choroidal Dystrophies | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1463 | Hereditary Retinal Dystrophies | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1465 | Nystagmus and Other Irregular Eye Movements | active | 2021-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1466 | Optic Atrophy | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1467 | Optic Neuritis | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1468 | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1469 | Other Background Retinopathy and Retinal Vascular Changes | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1471 | Other Disorders of Optic Nerve | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1473 | Other Endophthalmitis | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1475 | Prior Penetrating Keratoplasty | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1477 | Purulent Endophthalmitis | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1478 | Retinal Detachment with Retinal Defect | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1479 | Retinal Vascular Occlusion | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1480 | Other Proliferative Retinopathy | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1482 | Separation of Retinal Layers | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1483 | Visual Acuity 20/40 or Better | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1491 | Major Depressive Disorder Active | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1492 | Psych Visit Diagnostic Evaluation | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1496 | Psych Visit Psychotherapy | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1530 | Speech and Hearing Evaluation | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1558 | Morgagnian Cataract | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1559 | Macular Scar of Posterior Polar | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1560 | Best Corrected Visual Acuity Exam Using Snellen Chart | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1561 | Medications for Above Normal BMI | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1562 | Medications for Below Normal BMI | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1563 | Underweight | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1566 | Adult Depression Medications | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1567 | Adolescent Depression Medications | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1568 | Follow Up for Adult Depression | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1569 | Follow Up for Adolescent Depression | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1570 | Referral for Adolescent Depression | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1571 | Referral for Adult Depression | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1572 | High Intensity Statin Therapy | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1573 | LDL Cholesterol | active | 2025-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1574 | Low Intensity Statin Therapy | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1575 | Moderate Intensity Statin Therapy | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1576 | Outpatient Encounters for Preventive Care | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1578 | Follow Up Within 4 Weeks | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1580 | Referral to Primary Care or Alternate Provider | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1581 | Lifestyle Recommendation | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1582 | Patient Declined | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1583 | Referral or Counseling for Alcohol Consumption | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1584 | Hospice Care Ambulatory | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.3000 | Metformin | active | 2019-12 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.319 | Prostate Cancer | active | 2020-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.320 | Bone Scan | active | 2024-01 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.326 | Primary Open Angle Glaucoma | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.327 | Diabetic Retinopathy | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.353 | End Stage Renal Disease | active | 2020-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.362 | Asthma | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.366 | Arrhythmia | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.367 | Atrioventricular Block | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.368 | Cardiac Pacer in Situ | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.369 | Coronary Artery Disease No MI | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.370 | Hypotension | active | 2020-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.371 | Cardiac Surgery | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.376 | Heart Failure | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.378 | Pregnancy | active | 2021-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.398 | Prostate Cancer Treatment | active | 2025-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.399 | Salvage Therapy | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.401 | Prostate Specific Antigen Test | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.403 | Initial Myocardial Infarction | active | 2024-01 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.412 | Bradycardia | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.451 | Pain Warranting Further Investigation for Prostate Cancer | active | 2020-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.471 | Bilateral Oophorectomy | active | 2024-01 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.485 | Chemotherapy | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.509 | Tobacco Use Cessation Counseling | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1498 | Medications for Above Normal BMI | active | 2025-02 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1499 | Medications for Below Normal BMI | active | 2022-02 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1519 | Follow Up for Above Normal BMI | active | 2017-05 | us | hl7 | cms | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1523 | Follow Up for Above Normal BMI | active | 2017-08 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1524 | Follow Up for BMI Outside Normal Parameters | active | 2024-02 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1525 | Follow Up for Above Normal BMI | active | 2025-02 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1526 | Follow Up for Above Normal BMI | active | 2025-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1527 | Referrals Where Weight Assessment May Occur | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1528 | Follow Up for Below Normal BMI | active | 2022-03 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1549 | Follow Up for Below Normal BMI | active | 2023-02 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1550 | Follow Up for Below Normal BMI | active | 2023-02 | us | hl7 | cms | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1551 | Follow Up for Below Normal BMI | active | 2025-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1578 | Palliative Care | active | 2021-02 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113883.3.600.1.1579 | Palliative or Hospice Care | active | 2022-03 | us | hl7 | vsac |